Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 1.00 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | ARAF | P10398 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | BRAF | P15056 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 1.00 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 1.00 |
| ▸ | MYOC | Q99972 | 1/20 | 1.00 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 1.00 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw305074X SCHEMBL12199472 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| Gw305074X SCHEMBL29389948 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| Gw305074X SCHEMBL149922 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| Gw305074X SCHEMBL29392050 | 1.00 | RAF1 (1.00) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL5367163 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL1394784 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL4726411 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL8206335 | 0.87 | RAF1 (0.77) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL26245253 | 0.87 | RAF1 (0.77) | RAF1MAP1LC3BMAPTEGFRNTRK1 | |
| SCHEMBL10026597 | 0.87 | RAF1 (0.77) | RAF1MAP1LC3BMAPTEGFRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| CN-116036278-B | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240024283-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYOMAVIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-25 | — | — | US | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20220047552-A1 | RAF-1 KINASE INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | NESTLE SA (CH) | 2022-02-17 | — | — | US | claimed |
| EP-3852742-A1 | RAF-1 KINASE INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-07-28 | — | — | EP | claimed |
| EP-3801510-A1 | METHODS FOR TREATING MUSCULAR DYSTROPHIES | The Regents of the University of California (US) | 2021-04-14 | — | — | EP | claimed |
| CN-112654355-A | RAF-1 kinase inhibitor compounds for skeletal muscle modulation, methods and uses thereof | 雀巢产品有限公司 | 2021-04-13 | — | — | CN | claimed |
| EP-3222276-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND BIOMARKER FOR DRUG SCREENING | NAT DEFENSE MEDICAL CENTER (CN) | 2021-04-07 | — | — | EP | claimed |
| WO-2020058071-A1 | RAF-1 KINASE INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2020-03-26 | — | — | WO | claimed |
| US-20180186885-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-07-05 | — | — | US | claimed |
| US-9782393-B2 | Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2017-10-10 | — | — | US | claimed |
| EP-3222276-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND BIOMARKER FOR DRUG SCREENING | National Defense Medical Center (CN) | 2017-09-27 | — | — | EP | claimed |
| US-20160339004-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING | NAT DEFENSE MEDICAL CENTER (TW) | 2016-11-24 | — | — | US | claimed |
| US-9393234-B2 | Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2016-07-19 | — | — | US | claimed |
| US-20150150859-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING | NAT DEFENSE MEDICAL CT (TW) | 2015-06-04 | — | — | US | claimed |
| US-20140357676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2014-12-04 | — | — | US | claimed |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-10 | — | — | US | claimed |
| WO-2012021778-A2 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | claimed |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357676-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING | DAPK1, DAPK2, ARAF | RAF1 5/4885MAP1LC3B 2273/4885MAPT 4268/4885 |
| US-20100272717-A1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | ANXA5, BAX, ANXA6 | RAF1 2033/4885MAP1LC3B 3069/4885MAPT 4379/4885 |
| US-20160339004-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING | ARAF, DAPK1, DAPK2 | RAF1 5/4885MAP1LC3B 2223/4885MAPT 4165/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | RAF1 50/4885MAP1LC3B 2763/4885MAPT 2969/4885 |
| US-20150150859-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS FOR DRUG SCREENING | ARAF, DAPK1, DAPK2 | RAF1 5/4885MAP1LC3B 2223/4885MAPT 4165/4885 |
| US-20220047552-A1 | RAF-1 KINASE INHIBITOR COMPOUNDS FOR SKELETAL MUSCLE MODULATION, METHODS AND USES THEREOF | MYLK2, RAF1, MUSK | RAF1 2/4885MAP1LC3B 1008/4885MAPT 4734/4885 |
| US-20240024283-A1 | METHODS AND COMPOSITIONS FOR TREATING POLYOMAVIRUS | PML, PBK, MCTS1 | RAF1 2017/4885MAP1LC3B 764/4885MAPT 995/4885 |
| US-20130266636-A1 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION | BRAF, BUB1B, MKI67 | RAF1 25/4885MAP1LC3B 640/4885MAPT 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.